Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Study of ABC-14 Regimen ( AZA, Venetoclax and Chidamide) Compared With "3+7" Standard Induction Therapy or AB-14 (Venetoclax Combined With Azacitidine) for Newly Diagnosed Acute Myeloid Leukemia

NCT06451861 is registered in ClinicalTrials.gov with Guangdong Provincial People's Hospital as lead sponsor.

NCT NCT06451861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06451861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Study of ABC-14 Regimen ( AZA, Venetoclax and Chidamide) Compared With "3+7" Standard Induction Therapy or AB-14 (Venetoclax Combined With Azacitidine) for Newly Diagnosed Acute Myeloid Leukemia
Lead sponsor
Guangdong Provincial People's Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
August 21, 2024
Completion date
June 30, 2027
Enrollment
240 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia